Immunovaccine to Present New Pre-Clinical Data at the 2016 AACR Annual Meeting

HALIFAX, NOVA SCOTIA--(Marketwired - April 11, 2016) - Immunovaccine Inc. ("Immunovaccine" or the "company") (TSX:IMV)(OTCQX:IMMVF), a clinical stage vaccine and immunotherapy company, announced that new pre-clinical data on DPX™-based cancer vaccines will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting, which be held in New Orleans, Louisiana, April 16-20, 2016.

Dr. Genevieve Weir, research scientist at Immunovaccine, will present the abstract entitled "Multimodal therapy with a potent vaccine, metronomic cyclophosphamide and anti-PD-1 enhances immunotherapy of advanced tumors by increasing activation and clonal expansion of tumor infiltrating T cells." It will be presented as a poster (Abstract number 4903) on Wednesday April 20, 2016, from 8:00 a.m. to 12:00 p.m. CT in Section 23, Halls G-J, of the Ernest N. Morial Convention Center.

The poster highlights the effects of Immunovaccine's proprietary DepoVax™-based cancer vaccines, when used in combination with the chemotherapy cyclophosphamide and a PD-1 blockade. The full abstract is available on the AACR website.

About DepoVax™

DepoVax™ is a patented formulation that provides controlled and prolonged exposure of antigens plus adjuvant to the immune system, resulting in a strong, specific and sustained immune response with the potential for single-dose effectiveness. The DepoVax™ platform is flexible and can be used with a broad range of target antigens for preventative or therapeutic applications. The technology is designed to be commercially scalable, with the potential for years of shelf life stability.

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer). In collaboration with commercial and academic partners, Immunovaccine is also expanding the application of DepoVax™ as an adjuvanting platform for vaccines targeted against infectious diseases. Immunovaccine's goal in infectious diseases is to out-license its DepoVax™ platform to partners to generate earlier revenues. Connect at www.imvaccine.com.

Immunovaccine Forward-Looking Statements

This press release contains forward-looking information under applicable securities law. All information that addresses activities or developments that we expect to occur in the future is forward-looking information. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. However, they should not be regarded as a representation that any of the plans will be achieved. Actual results may differ materially from those set forth in this press release due to risks affecting the Company, including access to capital, the successful completion of clinical trials and receipt of all regulatory approvals. Immunovaccine Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.